Skip to content
MarketScale
‹ Back to IndustriesSciences

WHY 2018 IS THE YEAR TO GET YOUR DIGESTIVE TRACT BACK ON TRACK

You may be surprised to learn that your body is jam packed with trillions of bacteria. But don’t worry, most of these bacteria in your body are located in your gut, and they are actually doing good work for you! This little ecosystem, referred to as the gut microbiome, is constantly working to improve your digestion, enhance…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
WHY 2018 IS THE YEAR TO GET YOUR DIGESTIVE TRACT BACK ON TRACK

Key takeaways

01

You may be surprised to learn that your body is jam packed with trillions of bacteria.

02

But don’t worry, most of these bacteria in your body are located in your gut, and they are actually doing good work for you!

03

This little ecosystem, referred to as the gut microbiome, is constantly working to improve your digestion, enhance…

You may be surprised to learn that your body is jam packed with trillions of bacteria. But don’t worry, most of these bacteria in your body are located in your gut, and they are actually doing good work for you! This little ecosystem, referred to as the gut microbiome, is constantly working to improve your digestion, enhance your immune system, and protect you from harmful bacteria, all three of which are great reasons to focus on improving your gut health this year. The impact of gut health on overall well-being has been a very newsworthy topic in recent years. If you’ve been following the research and developments up until now, but haven’t taken the next step, then 2018 should be your year to do so, and here’s why.

The positive impact of a healthy gut has been proven time and time again. The gut microbiome contains thousands of different kinds of microbes, and is unique to each person. Strains of both good and bad bacteria exist in a delicate balance that effects your whole body. Not enough good bacteria, and functions such as digestion begin to degrade, leading to poor nutrient absorption, gas and bloating, even mental fogginess and weight fluctuations. With more good bacteria, functions such as digestion obviously improve, along with other functions that occur outside your gut, such as your ability to burn and store fat.

A healthy gut is not achieved from its bacterial make-up alone. Enzymes work with the gut microbiome to break down food into absorbable nutrients. If the body experiences a digestive enzyme deficiency, a healthy diet can go to waste as nutrients are not broken down and put to use in the body.

One of the most universally recommended methods to improve your gut health is through the use of enzymes and probiotics, good bacteria, either in foods or supplements. Without a healthy gut, a healthy diet can only go so far.

The long-term effects of a healthy gut can impact every part of your life. The GI tract is almost like a second brain, affecting moods, energy levels, libido, creative output, etc. Gastrointestinal health is extremely important to your overall well-being, which is why enzymes and probiotics are essential to restoring your intestines to a more optimal state. This can be achieved through both enzyme-rich raw foods and supplements.

But simply purchasing any supplement won’t solve your problems. When buying supplements, it is important to look at what they contain, and how much of it. When it comes to probiotics, be sure to check the specific strains and the Colony Forming Unit (CFU) number, which indicates the number of viable bacterial cells in each serving, to make sure that the supplement you choose is powerful enough to impact the flora in your gut. For enzymes, be aware that the potency of these ingredients isn’t measured in milligrams as you may be accustomed to seeing, but instead in varying Activity Units. A supplement facts panel that lists its enzymes measured by weight (in milligrams) may not have a high enough activity to make the difference you’re seeking.

Whether your preferred delivery method is foods or supplements, improving your gut health should be resolution #1 for a healthier 2018.

Deerland Enzymes & Probiotics is a leading specialty formulator and contract manufacturer of enzyme- and probiotic-based dietary supplements. With a team of industry experts working in a state-of-the-art lab, we’re positioned to serve customers from the initial stages of product conceptualization, through the design phase, and on to final formulation and contract manufacturing.

Read more at deerlandenzymes.com

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512